Roth MKM initiated coverage of Immix Biopharma (IMMX) with a Buy rating and $14 price target. The firm notes that clinical-stage Immix Biopharma is focused on developing highly differentiated therapies for cancer and autoimmune disease, and is in Phase 1b/2 clinical development with IMX-110 in first-line STS and with NXC-201 in rel/ref MM and rel/ref ALA. Roth MKM looks forward to Immix generating additional compelling clinical results to confirm the "impressive" balance of safety and efficacy it has already demonstrated. Close competitor Arcellx (ACLX) recently signed a commercialization deal worth $325 million just in upfront cash, 11 times Immix’s market value, the firm notes.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMMX:
- Immix’s Nexcella enters U.S. GMP manufacturing agreement for NXC-201 trial
- Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.
- Immix Biopharma’s Nexcella presents interim data from NEXICART-1 study
- Immix Biopharma doses first two patients in Phase 1b/2a combination trial
- Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
